Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice (Q41943954)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on January 2006

Language	Label	Description	Also known as
English	Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice	scientific article published on January 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

0 references

Paul Kay-Sheung Chan

7

object named as

Paul K S Chan

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

author name string

Dale L Barnard

1

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Craig W Day

2

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Kevin Bailey

3

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Matthew Heiner

4

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Robert Montgomery

5

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Larry Lauridsen

6

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Robert W Sidwell

8

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Antiviral Chemistry & Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

275-284

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Molecular mechanisms of resistance in antimalarial chemotherapy: the unmet challenge

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Severe acute respiratory syndrome, a pathological immune response to the new coronavirus--implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities.

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Coxsackievirus B4 infection of human fetal thymus cells

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Behavioral effects of mouse interferons-alpha and -gamma and human interferon-alpha in mice

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Potential antivirals and antiviral strategies against SARS coronavirus infections

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Aetiology: Koch's postulates fulfilled for SARS virus

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Characterization and inhibition of SARS-coronavirus main protease

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Coronavirus as a possible cause of severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity.

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Managing SARS amidst uncertainty

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Antiviral drug discovery against SARS-CoV.

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro

1 reference

https://api.crossref.org/works/10.1177%2F095632020601700505

21 January 2018

Identifiers

10.1177/095632020601700505

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41943954&oldid=2252971283"